New hope for deadly aortic tear: common drug could boost survival after emergency surgery
NCT ID NCT06968806
Summary
This study is testing if adding the anti-inflammatory drug ketorolac to standard emergency care helps patients recover better from a life-threatening tear in their main heart artery (Type A aortic dissection). 360 patients scheduled for emergency surgery will receive either ketorolac or a placebo injection and pills for two days after their operation, in addition to all standard treatments. Researchers will track serious complications, death rates, and signs of inflammation to see if the drug improves outcomes over 90 days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, Jiangsu, 210008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.